Literature DB >> 27746394

Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective.

J A Otter1, P Burgess2, F Davies3, S Mookerjee3, J Singleton3, M Gilchrist3, D Parsons3, E T Brannigan3, J Robotham4, A H Holmes5.   

Abstract

OBJECTIVE: To perform an economic evaluation on the cost associated with an outbreak of carbapenemase-producing Enterobacteriaceae (CPE).
METHODS: We performed an observational economic evaluation of an outbreak of CPE (NDM-producing Klebsiella pneumoniae) affecting 40 patients in a group of five hospitals across three sites in West London. Costs were split into actual expenditure (including anti-infective costs, enhanced CPE screening, contact precautions, temporary ward-based monitors of hand and environmental practice, and environmental decontamination), and 'opportunity cost' (staff time, bed closures and elective surgical missed revenue). Costs are estimated from the hospital perspective over the 10-month duration of the outbreak.
RESULTS: The outbreak cost €1.1m over 10 months (range €0.9-1.4m), comprising €312 000 actual expenditure, and €822 000 (range €631 000-€1.1m) in opportunity cost. An additional €153 000 was spent on Estates renovations prompted by the outbreak. Actual expenditure comprised: €54 000 on anti-infectives for 18 patients treated, €94 000 on laboratory costs for screening, €73 000 on contact precautions for 1831 contact precautions patient-days, €42 000 for hydrogen peroxide vapour decontamination of 24 single rooms, €43 000 on 2592 hours of ward-based monitors, and €6000 of expenditure related to ward and bay closures. Opportunity costs comprised: €244 000 related to 1206 lost bed-days (range 366-2562 bed-days, €77 000-€512 000), €349 000 in missed revenue from 72 elective surgical procedures, and €228 000 in staff time (range €205 000-€251 000). Reduced capacity to perform elective surgical procedures related to bed closures (€349 000) represented the greatest cost.
CONCLUSIONS: The cost estimates that we present suggest that CPE outbreaks are highly costly.
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbapenem; Carbapenem-resistant Enterobacteriaceae; Carbapenemase-producing Enterobacteriaceae; Cost; Economic evaluation; Klebsiella pneumoniae; New Delhi metallo-β-lactamase; Outbreak

Mesh:

Substances:

Year:  2016        PMID: 27746394     DOI: 10.1016/j.cmi.2016.10.005

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  33 in total

1.  Rapid detection of the main carbapenemases in Brazil directly from spiked blood culture using the RESIST-3 O.K.N. immunoassay.

Authors:  Priscila Lamb Wink; Amanda Silva Martins; Everton Inamine; Tanise Vendruscolo Dalmolin; Afonso Luís Barth
Journal:  Braz J Microbiol       Date:  2019-07-04       Impact factor: 2.476

2.  Rapid Detection of Carbapenemases in Enterobacteriaceae: Evaluation of the Resist-3 O.K.N. (OXA-48, KPC, NDM) Lateral Flow Multiplexed Assay.

Authors:  David W Wareham; Muhd Haziq F Abdul Momin
Journal:  J Clin Microbiol       Date:  2017-02-01       Impact factor: 5.948

3.  Reduced Incubation Time of the Modified Carbapenem Inactivation Test and Performance of Carbapenem Inactivation in a Set of Carbapenemase-Producing Enterobacteriaceae with a High Proportion of bla IMP Isolates.

Authors:  Rohan William Beresford; Michael Maley
Journal:  J Clin Microbiol       Date:  2019-06-25       Impact factor: 5.948

Review 4.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

5.  Clostridium difficile multidisciplinary team root cause analysis: impact on clinical care and circumvention of financial penalties posed by clinical commissioning groups, but at what cost?

Authors:  Kordo Saeed; Christina Petridou; Hazel Gray; Matthew Dryden; Karen Davis-Blues; Sheryl Lucero; Natalie Parker; Taryn Keyser; Tanya Matthews; Nick Cortes; Stephen Kidd; Claire Thomas; Heather Peacock; Joanna Hornzee; Bruce Wake
Journal:  J Infect Prev       Date:  2017-08-21

6.  The use of military planning techniques to manage outbreaks of novel infections in acute inpatient settings: development of an 'infection control estimate' (ICE).

Authors:  Matthew Oliver Wynn; Ryan George; Mark Cole
Journal:  J Infect Prev       Date:  2020-11-12

7.  Phenotypic and genotypic detection of carbapenemase production among gram negative bacteria isolated from hospital acquired infections.

Authors:  Sreeja K Vamsi; Rama S Moorthy; Mary N Hemiliamma; Rama B Chandra Reddy; Deepak J Chanderakant; Shravani Sirikonda
Journal:  Saudi Med J       Date:  2022-03       Impact factor: 1.422

8.  Fast and expensive (PCR) or cheap and slow (culture)? A mathematical modelling study to explore screening for carbapenem resistance in UK hospitals.

Authors:  Gwenan M Knight; Eleonora Dyakova; Siddharth Mookerjee; Frances Davies; Eimear T Brannigan; Jonathan A Otter; Alison H Holmes
Journal:  BMC Med       Date:  2018-08-16       Impact factor: 8.775

9.  Epidemiology and Transmission of Carbapenemase-Producing Enterobacteriaceae in a Health Care Network of an Acute-Care Hospital and Its Affiliated Intermediate- and Long-Term-Care Facilities in Singapore.

Authors:  Aung-Hein Aung; Kala Kanagasabai; Jocelyn Koh; Pei-Yun Hon; Brenda Ang; David Lye; Swaine L Chen; Angela Chow
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

10.  Emergence and clonal spread of colistin resistance due to multiple mutational mechanisms in carbapenemase-producing Klebsiella pneumoniae in London.

Authors:  Jonathan A Otter; Michel Doumith; Frances Davies; Siddharth Mookerjee; Eleonora Dyakova; Mark Gilchrist; Eimear T Brannigan; Kathleen Bamford; Tracey Galletly; Hugo Donaldson; David M Aanensen; Matthew J Ellington; Robert Hill; Jane F Turton; Katie L Hopkins; Neil Woodford; Alison Holmes
Journal:  Sci Rep       Date:  2017-10-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.